MerLion Pharmaceuticals is focusing on the development of finafloxacin; an atypical fluoroquinolone with outstanding safety profile and enhanced activity in acidified environments found in many infection sites (e.g. urine, abscesses, deep seated wounds, chronically infected tissues and stomach mucosa) and within the intracellular compartments of infected macrophages. Finafloxacin shows impressive activity against persistent and biofilm populations associated with chronic or recurring infections. Finafloxacin appears particularly well suited for treating severe infections in hospital settings, including complicated urinary tract, respiratory tract, skin and soft tissue, intra-abdominal and gastrointestinal infections.

Menu